1	Title: Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths
2	during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A
3	VEBIS-EHR Network Study
4	Authors : Baltazar Nunes ^{1*} , James Humphreys ¹ , Nathalie Nicolay ² , Toon Braeye ³ , Izaak Van
5	Evercooren ³ . Christian Holm Hansen ⁴ . Ida Rask Moustsen-Helms ⁴ . Chiara Sacco ^{5,6} . Massimo
6	Fabiani ⁵ , Jesús Castilla ^{7,8} , Iván Martínez-Baz ^{7,8} , Hinta Meijerink ⁹ , Ausenda Machado ¹⁰ , Patricia
7	Soares ¹⁰ , Rickard Ljung ¹¹ , Nicklas Pihlström ¹¹ , Anthony Nardone ¹ , Sabrina Bacci ² , Susana
8	Monge ^{12,13} , VEBIS-EHR working group
9	* Corresponding author
5	
10	Affiliations
11	¹ Epiconcept, Paris, France
12	² Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and
13	Control (ECDC), Solna, Sweden
14	³ Sciensano, Juliette Wytsmanstraat 14. 1050 Elsene, Belgium
15	⁴ Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut,
16	Copenhagen, Denmark
17	⁵ Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy
18	⁶ European Programme on Intervention Epidemiology Training (EPIET), European Centre for
19	Disease Prevention and Control, Stockholm, Sweden
20	⁷ Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain
21	⁸ CIBER on Epidemiology and Public Health, Spain
22	⁹ Norwegian Institute of Public Health (NIPH), Oslo, Norway
23	¹⁰ Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, 1600-609, Portugal
24	¹¹ Swedish Medical Products Agency, Uppsala, Sweden
	NOTE: This preprint reports new research that has not been certified by neer review and should not be used to quide clinical practice.

- 25 ¹² Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health
- 26 Carlos III, Madrid, Spain.
- 27 ¹³ CIBER on Infectious Diseases, Spain
- 28
- 29
- 30 **VEBIS-EHR working group**: Esther Kissling¹, Mario Fontán-Vela¹², Joris Van Loenhout³, Pierre
- 31 Hubin³, Alberto Mateo-Urdiales⁵, Daniele Petrone⁵, Patrizio Pezzotti⁵, Itziar Casado^{7,8}, Aitziber
- 32 Echeverria^{7,8}, Camino Trobajo-Sanmartín^{7,8}, Diana Lucas¹⁰.
- 33
- 34 **Corresponding author:**
- 35 Dr. Baltazar Nunes
- 36 Epiconcept, Paris, France
- 37 b.nunes@epiconcept.ft
- 38
- 39 Word count: 2,610
- 40 Abstract word count: 254

41 Abstract

42 Background

Monovalent XBB.1.5 vaccine was administered among those aged ≥65 years in EU/EEA countries
in autumn 2023; soon after SARS-Cov-2 BA.2.86/JN.1 lineages became dominant. We aimed to
estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalisations and
deaths during a period of BA.2.86/JN.1 predominance using a European multi-country study.

47 Methods

48 We linked electronic health record data to create historical cohorts in Belgium, Denmark, Italy, 49 Navarre (Spain), Norway, Portugal and Sweden. We included individuals aged ≥65 years eligible 50 for the autumnal 2023 COVID-19 vaccine with at least a primary series. Follow-up started when 51 ≥80% of country-specific sequenced viruses were BA.2.86/JN.1 lineages (4/12/23 to 08/01/24) 52 and ended 25/02/2024. At study site level, we estimated the overall vaccine confounder-53 adjusted (for age, sex, country's region, comorbidities and previous booster doses) hazard ratio 54 (aHR) of COVID-19 hospitalisations and deaths between individuals with ≥14 days after 55 vaccination and individuals unvaccinated in autumn 2023, as well as by time since vaccination 56 and stratified by age groups. VE was estimated as (1-pooled aHR)x100 with a random effects 57 model.

58 Results

XBB.1.5 VE against COVID-19 hospitalisations was 50% (95%CI: 45 to 55) and 41% (95%CI: 35 to
46) in 65-79-year-olds and in ≥80-year-olds respectively. VE against COVID19-related-death was
58% (95%CI: 42 to 69) and 48% (95%CI: 38 to 57), respectively, in both age groups. VE estimates
against each respective outcome declined in all age group over time.

63 Conclusion

- 64 Monovalent XBB.1.5 vaccine had a moderate protective effect against severe COVID-19 likely
- caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65.
- 66 Keywords: COVID-19, SARS-CoV-2, vaccine effectiveness, hospitalisation, cohort design,
- 67 electronic health records, multi-country study.

68 Introduction

69 In autumn 2023, COVID-19 vaccination campaigns were carried out in EU/EEA countries aiming 70 to reduce the risk of severe disease among the most vulnerable populations. The target groups 71 generally included those aged ≥60 or ≥65 years, persons living with comorbidities or conditions 72 that could increase the risk of severe disease, health professionals, and caregivers. The 73 monovalent Omicron XBB.1.5 vaccine was used in most EU/EEA countries and delivered as a 74 booster dose or primary vaccination during autumn/winter 2023/24. In January 2024 (1) the 75 median vaccine coverage among EU/EEA countries was 12% (range 0.01%-66.1%) and 17.1 76 (range 0.01%-89.3%), for those aged ≥60 or ≥80 years respectively - a range which indicates 77 variability between countries in terms of vaccine uptake. Eighty-two percent of the vaccines 78 administered during the autumn/winter 2023/24 campaign were Comirnaty Omicron XBB.1.5 79 (Pfizer BioNTech) vaccine (1).

In early autumn 2023, in EU/EEA countries, the XBB.1.5 lineage was predominant. The BA.2.86
and JN.1 SARS-CoV-2 lineages rapidly increased, gaining dominance in all EU/EEA countries by
mid-December (2).

Several studies reported XBB.1.5 vaccine effectiveness (VE) against severe disease in the first
months of the autumn/winter season at a time of XBB.1.5 predominance (3–6), including one
study conducted within the Vaccine Effectiveness Burden and Impact Studies project EHR
network (VEBIS-EHR) (4). These studies reported VE against COVID-19 hospitalisations ranging
between 62% to 74%, 52% to 74%, and 52% to 66% among those aged ≥18, ≥65 and ≥80 years
old respectively.

The BA.2.86 SARS-CoV-2 lineage presents more than 30 amino acid mutations compared to the XBB.1.5 lineage, and JN.1, a descendant of BA.2.86, harbours the L455S substitution at the receptor binding site. These mutations could provide immune escape capacities and reduce the effectiveness of the XBB.1.5 vaccine (7). However, studies of XBB.1.5 VE against severe disease 93 during periods of BA.2.86 or JN.1 predominance are still scarce (5,8). In this context, we aimed
94 to estimate XBB.1.5 VE against COVID-19-related hospitalisations and deaths overall and by time
95 since vaccination during a period of BA.2.86/JN.1 predominance within a European multi96 country study among older adults aged 65-79 and ≥80 years old.

97 Methods

This study was developed under the VEBIS-EHR network. The VEBIS project, funded by the
European Centre for Prevention and Disease Control (ECDC), aims to monitor COVID-19 VE using
linkage of electronic health records (EHR) within an EU/EEA multi-country setting. As of April
2024, seven countries participate in the VEBIS-EHR network: Belgium, Denmark, Italy, Spain
(Navarre), Norway, Portugal, and Sweden.

103 Detailed methods and the results of VEBIS-EHR studies have been published previously (9–11). 104 Briefly, using a common protocol (12) we developed a historical cohort study by reconstructing 105 study site cohorts of individuals aged 65 years or older resident in the and eligible to receive the 106 autumnal 2023 vaccine dose at the start of the country-specific vaccination campaign 107 (Supplementary material, Table S1, Annex 1), i.e., those aged 65 years or older, with primary 108 vaccination series completed at least 180 days ago and who, in the last 90 days, had no vaccine 109 dose administered nor documented SARS-CoV-2 infection or COVID-19 hospitalisation. Detailed 110 information on the eligibility criteria is presented in the Supplementary material, Annex 2. 111 Vaccination status, baseline characteristics, and outcome occurrence were obtained by linking 112 national/regional EHR. We defined BA.2.86/JN.1 lineage predominance period at the study-site 113 level, designating the period of predominance to have started by the date on which 80% of 114 sequenced samples were attributable to BA.2.86/JN.1 based on data extracted from the ECDC 115 European Respiratory Virus Surveillance Summary (ERVISS)(13) database and subset to the 116 countries of interest.

If the number of the weekly sequenced viruses was low, BA.2.86 frequency data from neighbouring countries were used as a proxy (Supplementary material, Annex 1). In Table S1 we present details on the start of BA.2.86 predominance period by study site. The end of the study period was 25 February in all study sites, approximately two months before data extraction (April 2024) to ensure EHR were sufficiently updated.

Among those identified as eligible at the start of the vaccination campaign (Supplementary material, Annex 2), we excluded all individuals hospitalised due to COVID-19 between the start of the vaccination campaign and the country-specific starting date of the study. Individual follow-up started at the beginning of the country-specific study period and ceased at the date of either the outcome, death for any cause, or the end of the study period - whichever was earliest. Vaccination status was treated as a time-dependent exposure, excluding the timeinterval 1-14 days post-vaccination from the analysis.

Hospitalisation due to COVID-19 was defined as a hospital admission due to a severe acute respiratory infection with a SARS-CoV-2 positive test from 14 days before to one day after admission, or with COVID-19 as the primary diagnosis in admission on discharge records. A COVID-19-related death was defined as a death with COVID-19 coded as cause, or death for any cause with a SARS-CoV-2 positive test in the 30 days preceding death.

134 We undertook a two-stage pooling of estimates calculated at the study-site level. In the first 135 stage, site-specific estimates of confounder-adjusted vaccine hazard ratios (aHR) and 95% 136 confidence intervals (95%CI) were calculated using Cox regression with calendar time as the 137 underlying scale adjusted by 5-year age groups, sex, region in the country, comorbidities, 138 number of vaccine booster doses received prior to the current vaccination campaign, and 139 nationality and socioeconomic status in some of the study sites (Supplementary material, Annex 140 3 and 4). In the second stage, study site-specific aHR estimates and standard errors were pooled 141 using a random-effects meta-analysis using Paule-Mantel method. Pooled VE was estimated as

(1-pooled aHR)x100. To assess heterogeneity, we used the I^2 index (14). A fixed-effects model
was used as a secondary analysis.

144 Results

At the end of the individual observation period, we included 13,907,924 and 6,533,724 persons across both age groups, in the unvaccinated and vaccinated cohorts, respectively. Among the vaccinated cohorts, at the end of the observation period, 2,604,152 (39.9%) and 3,929,572 (60.1%) belonged, respectively, to those who were vaccinated 14 to 89 days and 90 to 179 days. The proportion of individuals with high-risk comorbidities (7.3% vs 2.6%) and with a greater

number of previous booster doses (≥2 boosters: 92.3% vs 33.1%) was higher among vaccinated
than unvaccinated. Further, but to a lesser extent, vaccinated persons with a longer time since
vaccination (90-179 days) also had a greater frequency of high-risk comorbidities (9.0% vs 4.8%)
and a greater number of previous boosters (≥2 boosters: 94.3% vs 89.4%) doses compared to
those vaccinated with less time since vaccination (14-90 days) (Table 1).

In the 65-79 years age group there were 1,765 hospitalisation events among 17.8 million personmonths at risk in unvaccinated, and 908 COVID-19 hospitalisations events among 9.9 million person-months at risk in vaccinated persons. XBB.1.5 COVID-19 VE against COVID-19 hospitalisations was 50% (95%CI: 45 to 55) overall, 51% (95%CI: 45 to 56) and 47% (95%CI: 32 to 59) among those who received the vaccine respectively between 14 to 89 days and 90 to 179 days.

In ≥80 years age-group, there were 2,130 COVID-19 hospitalisation events among 7.0 million
person-months at risk in unvaccinated, and 1,306 among 4.1 million person-months at risk in
vaccinated persons. VE was 41% (95%CI: 35 to 46) overall and 42% (95%CI: 36 to 47) and 38%
(95%CI: 17 to 54%) by time since vaccination among those who received the vaccine between
14 to 89 days and 90 to 179 days, respectively.

In the 65–79-year age-group there were 256 COVID-19 related deaths among 15.9 million person-months at risk in unvaccinated, and 151 among 7.8 million person-months at risk in vaccinated individuals. XBB.1.5 COVID-19 VE estimates against COVID-19-related deaths, was 58% (95%CI: 42 to 69) overall, 59% (95%CI: 41 to 72) and 54% (95%CI: -17 to 82) respectively among those who received the vaccine between 14 to 89 days and 90 to 179 days.

In the ≥80-year age-group, there were 570 COVID-19 related deaths event among 6.6 million
person-months at risk in unvaccinated, and 389 among 3.4 million person-months at risk in
unvaccinated persons. The XBB.1.5 COVID-19 was 48% (95%CI: 38 to 57) overall, 51% (95%CI: 42
to 59) and 9% (95%CI: -86 to 56%) among those who received the vaccine between 14 to 89 days
and 90 to 179 days, respectively (Table 2).

There was low to moderate heterogeneity between study sites' aHR estimates among pooled VE estimates (I²=0% to 77%). High heterogeneity (I²=77%) was observed in the VE estimate against death within 90-179 days since vaccination for the 80+ cohort, leading to a very wide 95% confidence interval for this estimate. Fixed effects pooled estimates were similar to the random effect estimates presented in the primary analysis (Supplementary figures – Annex 6).

181 Discussion

182 Our results indicate that in the population aged 65 years and older, the 2023 autumnal 183 monovalent XBB.1.5 booster conferred protection against severe COVID-19 outcomes during 184 the period in which COVID-19 cases were likely to be caused by the Omicron BA.2.86 or JN.1 185 lineages. These estimates of protection represent a reduction in risk that ranged from 42% to 186 51% for COVID-19 hospitalisation and from 51 to 59% for COVID-19 deaths for those who 187 received the vaccine in the last three months, and were consistently lower among those aged 188 \geq 80 years. For those vaccinated, but with more time since vaccination (three or more months) 189 during the BA.2.86/JN.1 predominance period, XBB.1.5 vaccine presented lower levels of 190 protection against COVID-19 hospitalisations, ranging from 38% to 47%, and against COVID-19

related deaths ranging from 9% to 54% though, as discussed earlier, the latter estimates againstCOVID-19-related deaths had low precision.

193 Our results suggest a lower VE among those who received a vaccine between 14 and 89 days in 194 the BA.2.86/JN.1 predominant period, compared to the XBB predominant period estimates 195 obtained in the VEBIS-EHR network (4). Specifically, in the 65–79-year-old XBB.1.5 VE against 196 hospitalisations decreased from 64% (95%CI 55 to 72) in the XXB period to 51% (95%CI 45 to 56) 197 in the BA 2.86/JN1 period and for those ≥80 years from 65% (95%Cl 56 to 71) to 42% (95%Cl 36 198 to 47). The XBB.1.5 VE against COVID-19-related deaths declined in those aged 65-79 years from 199 67% (95%CI: 42 to 81) to 59% (95%CI 41 to 72) and in those ≥80 years from 67% (95%CI: 41 to 200 81) to 51% (95%CI: 42 to 59). These differences could be due to higher natural immunity in the 201 comparison group due to recent SARS-CoV-2 infection, although other studies employing 202 different study designs have also found evidence of reduced vaccine effectiveness against 203 BA.2.86/JN.1 relative to XBB.1.5 (15).

204 Our results are concordant with results from other studies that estimated COVID-19 VE against 205 severe outcomes potentially due to XBB sub-lineages or JN.1 SARS-CoV-2 lineages. A test-206 negative design study conducted in England (8) in the population aged 65 years or more showed 207 a decrease in VE against hospitalisations from 74% (95%CI: 62% to 82%) against XBB sub-lineages 208 to 37% (95%CI: -20 to 66) against JN.1, for those who were vaccinated 2-4 weeks after 209 vaccination before. Similar results were also observed in two studies conducted in the United 210 States (5,6) that aimed to estimate XBB.1.5 VE against hospitalisations likely due to XBB sub-211 lineages versus JN.1 among individuals aged ≥18 years. In both studies, a reduction in the 212 protection of XBB.1.5 vaccine against COVID-19 hospitalisations was observed within the first 60 213 days after vaccination, respectively from 62% (95%CI: 44% to 74%) to 32% (95%CI: 3% to 52%) 214 (5), and from 74% (95%CI: 49% to 87%) to 50% (95%CI: 15% to 71%) (6).

215 The results presented here should be interpreted cautiously, considering the potential presence 216 of confounding bias, given its observational nature, and the possible misclassification of the 217 vaccine status and outcome once we used an EHR-based multicentre study. The vaccine status 218 hazard ratios were adjusted for several potential confounding factors at the study site level. Still, 219 although this adjustment was made, we cannot exclude the presence of confounding residual 220 bias from our analysis. Considering misclassification of the exposure, vaccination information 221 was extracted from national vaccination registries and measured prior to, and independently of, 222 the outcome. Estimates of 2023 autumnal COVID-19 vaccine coverage observed within our EHR-223 based study population were very close to the officially reported equivalents produced by the 224 ECDC (Supplementary, Annex 6, Table S5). We considered our VE estimate representative of 225 XBB.1.5 vaccine performance given that 98.3% (Table 1) of the vaccines received during the 226 study period were the monovalent XBB.1.5. Among these, 99% were the Pfizer Comirnaty 227 XBB.1.5-adapted vaccine, which indicates that our VE estimates represent the effectiveness of 228 this vaccine brand in general.

229 Additionally, we cannot rule out the presence of misclassification or underreporting of COVID-230 19 hospitalisations and deaths, even using national hospitalisations, death and laboratory 231 registries given the lag between event and full recording of such events in the relevant EHRs, 232 and also due the reduction in SARS-CoV-2 testing that would underestimate COVID-19 related 233 deaths identification. To reduce the effect of misclassification bias due to unextracted events, 234 or otherwise due to extraction of incomplete records, a two-month delay between the end of 235 the study period (i.e., the last possible event) and extraction of data from source EHRs has been 236 implemented. For the purpose of this analysis, no EHR extractions were undertaken until at least 237 April 2024. Nevertheless, we do not expect that misclassification of the outcome could be 238 differential by the vaccine status. If underreporting of events is present in our data, we do not 239 expect a bias to arise from it, only a loss in the number of events and statistical power. On the

other hand, if non-COVID-19 hospitalisation are classified as COVID-19 event, we expect that our
estimates would be biased to the null effect (16).

Another issue to be addressed, will be the high diffusion of self-diagnosis through at-home testing and the possible under-ascertainment of asymptomatic and mild cases, it is likely that some SARS-CoV-2 infections were not reported, thus leading to a possible overestimation of the eligible individuals at the start of the vaccination campaigns. This was likely more frequent in those who did not receive the seasonal booster, possibly causing an underestimation of VE.

247 The comparison of VE by time since XBB.1.5 administration among different epidemic phases, 248 like XXB vs BA.2.86 predominance periods, should be interpreted with cautions because of the 249 possible different unmeasured characteristics among persons who received the seasonal 250 booster at different times. For example, those who received the booster dose later might be 251 generally less prone to adopt preventive measures and therefore have had a higher exposure to 252 risky behaviours than those who received it earlier. Additionally, individuals with a recent 253 infection will be higher among unvaccinated persons during BA.2.86/JN.1 period. Both these 254 situations could have resulted in a relative underestimation of VE during the BA.2.86/JN.1 255 predominance period, and a slight overestimation of VE in the XBB predominance period.

Despite the limitations described above, our study also has several strengths. As we employed mostly national registries, large sample sizes and a large number of events were reported by study sites, leading to a high precision around VE estimates and allowing stratified VE estimates. Additionally, the fact that the study was conducted in seven different EU/EEA countries using a common scientific protocol published ahead of the study development (12), and the low to moderate heterogeneity observed between study-level VE estimates, reinforce the consistency and reproducibility of the results in the participating study sites.

In conclusion, our XBB.1.5 VE estimates against severe COVID-19, likely caused by BA.2.86/JN.1,
 were lower than those observed during the XBB.1.5 lineage predominance period. Nevertheless,

the results of our study indicate that the XBB.1.5 vaccine offered moderate protection (\geq 40%)

for up to six months after vaccination against severe COVID-19, likely caused by BA.2.86/JN.1,

267 during the 2023/2024 winter in older (\geq 65 years old) populations.

268 Acknowledgments

269 The authors would like to thank all the people from the study sites involved in the data collection

270 and for producing estimates of VE, as without their work these results wouldn't be available for

the scientific community and the public.

We gratefully acknowledge all data contributors, i.e., the Authors and their Originating laboratories responsible for obtaining the specimens, and their Submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based.

276 Ethics

All study sites participating in this study conformed with their respective national and EU ethical
and data protection requirements. Ethical statements for each of the participating study sites:

279 Belgium: Data linkage and collection within the data-warehouse have been approved by the 280 information security committee. The study was conducted in accordance with the Declaration 281 of Helsinki. Ethical approval was granted for the gathering of data from hospitalized patients by 282 the Committee for Medical Ethics from the Ghent University Hospital (reference number BC-283 07507) and authorization for possible individual data linkage using the national register number 284 from the Information Security Committee (ISC) Social Security and Health (reference number 285 IVC/KSZG/20/384). Linkage of hospitalized patient data to vaccination and testing within the 286 LINK-VACC project was approved by the Medical Ethics Committee UZ Brussels–VUB on 3 287 February 2021 (reference number 2020/523), and authorization from the ISC Social Security and 288 Health (reference number IVC/KSZG/21/034).

289 **Denmark:** Only administrative register data was used for the study. According to Danish law, 290 ethics approval is exempt for such research, and the Danish Data Protection Agency, which is 291 dedicated ethics and legal oversight body, thus waives ethical approval for the study of 292 administrative register data when no individual contact of participants is necessary, and only 293 aggregate results are included as findings. The study is, therefore, fully compliant with all legal 294 and ethical requirements, and there are no further processes available regarding such studies.

295 Navarre (Spain): The study was approved by Navarre's Ethical Committee for Clinical Research,

which waived the requirement of obtaining informed consent.

297 Norway: Ethical approval was granted by Regional Committees for Medical and Health Research

298 Ethics (REC) Southeast (reference number 122745). The Norwegian Institute of Public Health has

299 performed a Data Protection Impact Assessment (DPIA) for Beredt C19.

Portugal: The study received approval from the Ethical Committee and the Data Protection
 Officer of the Instituto Nacional de Saúde Doutor Ricardo Jorge. Given that data was irreversibly
 anonymised, the need for the participants' informed consent was waived by the Ethical
 Committee.

304 Italy: This study, based on routinely collected data, will not be submitted for approval to an 305 ethical committee because the dissemination of COVID-19 surveillance data was authorized by 306 the Italian law N. 52 of 19 May 2022, following the law decree N. 24 of 24 March 2022 (Article 307 n. 13). Based on the same acts, the information on COVID-19 vaccination was retrieved by the 308 Italian National Institute of Health using data from the National Immunisation Information 309 System of the Italian Ministry of Health. Because of the retrospective design and the large size 310 of the population under study, in accordance with the Authorization n. 9 released by the Italian 311 data protection authority on 15 December 2016, the individual informed consent was not 312 requested for the conduction of this study.

Sweden: The Swedish study is approved by the Swedish Ethical Review Authority (2020-06859,

314 2021-02186) and has conformed to the principles embodied in the Declaration of Helsinki.

315 Consent to participate is not applicable as this is a register-based study.

316 Funding

All the public health organizations involved received funding from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 'Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries' (RS/2022/DTS/24104). In Portugal, this work was also supported by FCT – Fundação para a Ciência e Tecnologia, I.P. by project reference (EECINST/00049/2021/CP2817/CT0001 and DOI identifier

323 10.54499/CEECINST/00049/2021/CP2817/CT0001

Data Availability: Authors cannot share the data used for this study, which should be requested

325 to the data owner institutions following their respective procedures.

326 **Conflict of interest**: Authors declare no competing interests.

327 Author contribution: SB, NN, BN, JH and SM conceived the study and BN, JH, NN and SM 328 conceited the methods. All authors from Public Health institutions at each study site were 329 responsible for the data management and analysis at the site level. JH was in charge of pooling 330 site estimates, with the help of SM. BN drafted the first version of the manuscript, with the help 331 of JH and SM, AN, and EK. All the authors contributed to the interpretation of the results and 332 critically reviewed the manuscript. All the authors approved the final version of this manuscript. 333 All the authors within the VEBIS-EHR working group made a substantial contribution to the 334 conception or design of the work, critically revised the manuscript, provided their final approval 335 of the version to be published, and agreed to be accountable for all aspects of the work.

336 References

European Centre for Disease Prevention and Control. Interim COVID-19 vaccination
 coverage in the EU/EEA during the 2023–24 season campaigns [Internet]. ECDC; 2024
 [cited 2024 May 28]. Available from: https://www.ecdc.europa.eu/en/publications data/interim-covid-19-vaccination-coverage-eueea-during-2023-24-season-campaigns

- European Centre for Disease Prevention and Control. Communicable disease threats
 report, 17-23 December 2023, week 51. ECDC; 2023.
- Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-Branth P.
 Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation
 in Denmark: a national cohort study. Lancet Infect Dis. 2024 Feb 1;24(2):e73–4.
- Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
 Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5
 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network
 Study. Influenza Other Respir Viruses. 2024 Apr;18(4):e13292.
- Caffrey AR, Appaneal HJ, Lopes VV, Puzniak L, Zasowski EJ, Jodar L, et al. Effectiveness of
 BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. medRxiv. 2024 Jan
 1;2024.04.05.24305063.
- Tartof SY, Slezak JM, Puzniak L, Frankland TB, Ackerson BK, Jodar L, et al. Effectiveness of
 BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages. medRxiv. 2024 Jan
 1;2024.05.04.24306875.
- Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-2 BA.2.86
 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2024 Feb 1;24(2):e70–2.
- Kirsebom FCM, Stowe J, Lopez Bernal J, Allen A, Andrews N. Effectiveness of autumn 2023
 COVID-19 vaccination and residual protection of prior doses against hospitalisation in
 England, estimated using a test-negative case-control study. J Infect. 2024 May
 7;89(1):106177.
- Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of
 COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using
 electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March
 2022. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2022 Jul;27(30).
- Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic
 health registries in ≥65 years old population in six European countries, October 2021 to
 November 2022. Influenza Other Respir Viruses. 2023 Nov;17(11):e13195.
- Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
 Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years:
 results from a VEBIS network, Europe, October 2021 to July 2023. Vol. 29,
 Eurosurveillance. 2024. p. 2300670.
- European Centre for Disease Prevention and Control. Protocol for a COVID-19 vaccine
 effectiveness estimation using health data registries, VEBIS multi-country study Version
 2.0 [Internet]. ECDC; 2024 [cited 2024 May 28]. Available from:
 https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-
- 378 effectiveness-estimation-using-health-data-registries
- European Centre for Disease Prevention and Control. European Respiratory Virus
 Surveillance Summary (ERVISS) [Internet]. 2024 [cited 2024 Jun 27]. Available from: https://erviss.org/

- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002
 Jun 15;21(11):1539–58.
- Moustsen-Helms IR, Bager P, Larsen TG, Møller FT, Vestergaard LS, Rasmussen M, et al.
 Relative vaccine protection, disease severity, and symptoms associated with the SARSCoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide
 observational study. Lancet Infect Dis [Internet]. [cited 2024 Jun 20]; Available from:
 https://doi.org/10.1016/S1473-3099(24)00220-2
- 16. Hansen CH. Bias in vaccine effectiveness studies of clinically severe outcomes that are
 measured with low specificity: the example of COVID-19-related hospitalisation. Euro
- 391 Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2024 Feb;29(7).

392

Table 1. Descriptive characteristics of the study population (N= 20,441,648) by vaccination

394 status and time since vaccination at the end of the study period*, within the seven study sites

395 (Belgium, Denmark, Italy, Navarre-Spain, Norway, Portugal, and Sweden during BA.2.86/JN.1

396 predominant period (from 4 December 2023 until 25 February 2024): VEBIS-EHR network.

days days days days n(%) n(%) n(%) n(%) n(%) n(%) Total (row % over total = 13,907,924 6,533,724 2,604,15212.7) 3,929,572(25.2) 20,40,680) (68) (32.0) 989,830 (25.2) Belgium 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 989,830 (25.2) Navarre 445,563 (0.3) 154,610 (2.4) 80,626 (3.1) 74,348 (1.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugal 1,100,484 (7.9) 1,251,091 (19.2) 325,366 (12.5) 92,762,215 (70.3) Age group (vers) 65-79 9,849,304 (70.8) 4,566,138 (69.8) 1,796,923 (69.0) 2,763,215 (70.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,229,717 (48.4) 1,484,583 (47.0) Medium/low risk comorbidities 8,579,525 (61.7) 2,783,521 (42.6) 1,201,668 (46.1) 2,055,158 (52.3)	Variable	Not vaccinated	Vaccinated ≥14	Vaccinated 14-89	Vaccinated 90-179
n (%) n (%) n (%) n (%) n (%) n (%) 20,440,689) (68) (32.0) 3,929,572(25.2) 20,440,689) (68) (32.0) Study site 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 989,830 (25.2) Denmark 219,481 (16.) 894,411 (13.7) 100,989 (3.9) 793,422 (20.2) Italy 10,750,561 (77.3) 1,296,646 (19.8) 984,379 (37.8) 312,20,85 (7.9) Navarre 45,563 (0.3) 154,610 (2.4) 80,262 (3.1) 74,348 (19.9) Norway 397,240 (2.9) 525,048 (8.0) 160,624 (6.2) 364,49 (3.9) Portugal 1,00,4849 (7.9) 2,25,091 (19.2) 325,366 (12.5) 92,725 (23.6) Age group (years) 65-79 9,440,304 (70.8) 4,560,138 (69.8) 1,766,523 (69.0) 2,763,215 (70.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Male 7,760,080 (55.8) 3,428,717 (52.5) 1,237,07 (4.8) 354,852 (9.0) Mocomorbidities 8,			days	days	days
Total (row % over total = 13,907,924 6,533,724 2,604,15212.7) 3,929,572(25.2) Study site (68) (32.0) (32.0) (32.0) Study site 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 989,830 (25.2) Denmark 219,481 (1.6) 894,411 (13.7) 100,989 (3.9) 793,422 (20.2) Navare 45,563 (0.3) 154,610 (2.4) 80,626 (2.1) 74,438 (1.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Age group (years) - - - - - 65-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (69.0) 2,763,215 (70.3) 5ex -		n (%)	n (%)	n (%)	n (%)
20,40,689) (68) (32.0) Study site Belgium 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 989,830 (25.2) Denmark 219,481 (1.6) 894,411 (13.7) 100,989 (3.9) 793,422 (20.2) Navarre 45,563 (0.3) 154,610 (2.4) 80,423 (7) 312,085 (7.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugal 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,725 (23.6) Age group (years) 55-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (69.0) 2,763,215 (7.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Fermale 6,147,822 (44.2) 3,105,006 (47.5) 1,23,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,4852 (9.0) Medium/low risk comorbidities 355,038 (2.6) 478,559 (Total (row % over total =	13,907,924	6,533,724	2,604,15212.7)	3,929,572(25.2)
Study site Belgium 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 989,830 (25.2) Nemmark 219,481 (1.6) 894,411 (13.7) 100,999 (3.9) 793,422 (20.2) Navare 445,563 (0.3) 154,610 (2.4) 80,262 (3.1) 74,348 (1.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (3.3) Portugal 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,725 (23.6) Sweden 457,647 (3.3) 1,346,539 (20.6) 876,741 (33.7) 469,798 (12.0) Age group (years) - - - - - 65-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (69.0) 1,763,215 (70.3) Sex - <td< td=""><td>20,440,689)</td><td>(68)</td><td>(32.0)</td><td></td><td></td></td<>	20,440,689)	(68)	(32.0)		
belgium 936,583 (6.7) 1,065,561 (16.3) 75,731 (2.9) 998,830 (25.2) Lialy 10,750,561 (77.3) 1,296,464 (19.8) 998,379 (37.8) 312,065 (7.9) Navarre 45,563 (0.3) 154,610 (2.4) 80,062 (1.3) 74,348 (1.9) Norway 397,240 (2.9) 252,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugal 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,725 (23.6) Age group (years) - - - - - 65-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (90.0) 2,763,215 (70.3) Sex - <td>Study site</td> <td></td> <td></td> <td></td> <td></td>	Study site				
Denmark 219,481 (1.6) 894,411 (13.7) 100,98 (3.9) 793,422 (20.2) Navarre 45,563 (0.3) 1.296,464 (19.8) 984,379 (37.8) 312,085 (7.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugi 1.100,849 (7.9) 1.25,109 (19.2) 325,366 (12.5) 925,752 (23.6) Sweden 457,647 (3.3) 1.346,539 (20.6) 876,741 (33.7) 469,798 (12.0) Age group (years) 65-79 9,849,304 (70.8) 4,566 (30.2) 807,229 (31.0) 1,166,357 (29.7) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,05,006 (47.5) 1,259,714 (44.4) 1,845,835 (47.0) Mising 2 (20.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** 4,947,387 (35.6) 3,256,262 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,566,741 (33.6) Medium/low risk comorbidities 8,579,525 (61.7) <td>Belgium</td> <td>936,583 (6.7)</td> <td>1,065,561 (16.3)</td> <td>75,731 (2.9)</td> <td>989,830 (25.2)</td>	Belgium	936,583 (6.7)	1,065,561 (16.3)	75,731 (2.9)	989,830 (25.2)
taly 10,750,551 (77.3) 1,296,464 (19.8) 984,379 (37.8) 312,055 (7.9) Navarre 45,563 (0.3) 154,610 (2.4) 80,262 (3.1) 74,348 (1.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugal 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,725 (23.6) Age group (years) - - 280 4,058,620 (29.2) 1,973,586 (30.2) 807,229 (31.0) 1,166,357 (29.7) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,234,981 (51.6) 2,083,736 (53.0) Comorbidities** 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,825 (9.0) Medium/low risk comorbidities 4,947,887 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) Number of previous booster - - 2,006 (0.1) 12,821 (0.3) Number of previous booster - - 2,926,39 (64.7) 1,443,946 (55.5) 2,785,69 (7.9) <td< td=""><td>Denmark</td><td>219,481 (1.6)</td><td>894,411 (13.7)</td><td>100,989 (3.9)</td><td>793,422 (20.2)</td></td<>	Denmark	219,481 (1.6)	894,411 (13.7)	100,989 (3.9)	793,422 (20.2)
Navarre 45,563 (0.3) 154,610 (2.4) 80,262 (3.1) 74,348 (1.9) Norway 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 364,364 (9.3) Portugal 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,752 (2.3.6) Age group (years) - - 457,647 (3.3) 1,346,539 (20.6) 876,741 (33.7) 469,798 (12.0) Age group (years) - - - 9,849,304 (70.8) 4,566,138 (69.8) 1,796,923 (69.0) 2,763,215 (70.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,259,171 (48.4) 1,845,835 (47.0) Medium/low risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 2,055,185 (53.3) No comorbidities ** Missing 2,907 (4.2) 2,006 (0.1) 1,566,741 (33.3) No comorbidities * 3,54,852 (54.1) 2,28,59 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,566,741 (33.3) Number of previous booster - - <td< td=""><td>Italy</td><td>10,750,561 (77.3)</td><td>1,296,464 (19.8)</td><td>984,379 (37.8)</td><td>312,085 (7.9)</td></td<>	Italy	10,750,561 (77.3)	1,296,464 (19.8)	984,379 (37.8)	312,085 (7.9)
Norway Portugal 397,240 (2.9) 525,048 (8.0) 160,684 (6.2) 564,364 (9.3) Age group (years) 457,647 (3.3) 1,246,539 (20.6) 325,366 (12.5) 925,725 (23.6) Age group (years) 55-79 9,849,304 (70.8) 4,556,20 (29.2) 1,975,586 (30.2) 807,229 (31.0) 1,166,357 (27.7) Sex	Navarre	45,563 (0.3)	154,610 (2.4)	80,262 (3.1)	74,348 (1.9)
Portugal Sweden 1,100,849 (7.9) 1,251,091 (19.2) 325,366 (12.5) 925,725 (23.6) Age group (years) 437,647 (3.3) 1,346,539 (20.6) 876,741 (3.7) 449,798 (12.0) Age group (years) 55-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (69.0) 2,763,215 (70.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,223,707 (4.8) 354,835 (47.0) Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 1 (0.0) Comorbidities** 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.9) Medium//tow risk comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster 2 4,038,88 (29.0) 4,422,639 (64.7) 1,434,946 (55.5) 2,785,536 (70.9) 3 5,462 (39) 1,507,525 (23.1) 72,1889 (27.7) 785,536 (20.0) Number of previous booster 2 4,038,888 (29.0) 4,229,639 (64.7) <	Norway	397,240 (2.9)	525,048 (8.0)	160,684 (6.2)	364,364 (9.3)
Sweden 457,647 (3.3) 1,346,539 (20.6) 876,741 (33.7) 469,798 (12.0) Age group (years) -	Portugal	1,100,849 (7.9)	1,251,091 (19.2) 325,366 (12		925,725 (23.6)
Age group (years) 1 <th1< th=""> 1 1</th1<>	Sweden	457,647 (3.3)	1,346,539 (20.6)	876,741 (33.7)	469,798 (12.0)
65-79 9,849,304 (70.8) 4,560,138 (69.8) 1,796,923 (69.0) 2,763,215 (70.3) Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,259,171 (48.4) 1,845,385 (47.0) Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) Number of previous booster doss 0 1,598,986 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2,785,693 (70.9) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 3 546,308 (3.9) 1,507,255 (23.1) 724,889 (10.0) 2,765,693 (70.9) <td>Age group (years)</td> <td>, , ,</td> <td></td> <td></td> <td>, , ,</td>	Age group (years)	, , ,			, , ,
≥80 4,058,620 (29.2) 1,973,586 (30.2) 807,229 (31.0) 1,166,357 (29.7) Sex	65-79	9.849.304 (70.8)	4.560.138 (69.8)	1.796.923 (69.0)	2.763.215 (70.3)
Sex Male 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Female 6,147,822 (44.2) 3,105,006 (47.5) 1,259,171 (48.4) 1,845,835 (47.0) Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** High risk comorbidities 3,55,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 771,898 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 133,4795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) 4 16,925 (0.1)	≥80	4.058.620 (29.2)	1.973.586 (30.2)	807.229 (31.0)	1.166.357 (29.7)
Male Female 7,760,080 (55.8) 3,428,717 (52.5) 1,344,981 (51.6) 2,083,736 (53.0) Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) Number of previous booster 65,79,256 (61.7) 2,783,512 (42.6) 1,277,149.00 1,506,741 (48.3) Number of previous booster 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (53.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 <	Sex	,,,,	// / /		, - , , - ,
Female 6,147,822 (44.2) 3,105,006 (47.5) 1,259,171 (48.4) 1,845,835 (47.0) Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (2.90) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 4 16,925 (0.1) 216,458 (4.5) 161,663 (6.2) 134,795 (3.4) 4 16,925 (0.1) </td <td>Male</td> <td>7.760.080 (55.8)</td> <td>3.428.717 (52.5)</td> <td>1.344.981 (51.6)</td> <td>2.083.736 (53.0)</td>	Male	7.760.080 (55.8)	3.428.717 (52.5)	1.344.981 (51.6)	2.083.736 (53.0)
Missing 22 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) Comorbidities** High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster 25,974 (0.2) 14,827 (0.2) 2,006 (0.1) 12,821 (0.3) Number of previous booster 4 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,963 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,922 (0.1) 286,458 (4.5) 161,663 (6.2) 134,795 (3.4) 4 16,922 (0.1) 26,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,5124 (0	Female	6.147.822 (44.2)	3.105.006 (47.5)	1.259.171 (48.4)	1.845.835 (47.0)
Comorbidities** High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (biaalent original/BA.1) 11 (0.0) 10 (0.0) <	Missing	22 (0.0)	1 (0.0)	0 (0.0)	1 (0.0)
High risk comorbidities 355,038 (2.6) 478,559 (7.3) 123,707 (4.8) 354,852 (9.0) Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Missing 25,974 (0.2) 14,827 (0.2) 2,006 (0.1) 12,821 (0.3) Number of previous booster 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6)	Comorbidities**	(<i>)</i>	()	- ()	()
Medium/low risk comorbidities 4,947,387 (35.6) 3,256,826 (49.8) 1,201,668 (46.1) 2,055,158 (52.3) No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster 25,974 (0.2) 14,827 (0.2) 2,006 (0.1) 12,821 (0.3) Number of previous booster 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6)	High risk comorbidities	355.038 (2.6)	478.559 (7.3)	123,707 (4.8)	354.852 (9.0)
No comorbidities 8,579,525 (61.7) 2,783,512 (42.6) 1,276,771 (49.0) 1,506,741 (38.3) Number of previous booster doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (bivalent 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (bivalent 11 (0.0) 1 (0.0) 40 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (Mba.4/BA.5) 98 (0.0) 5 (0.0)	Medium/low risk comorbidities	4.947.387 (35.6)	3,256,826 (49,8)	1.201.668 (46.1)	2.055.158 (52.3)
Missing 25,974 (0.2) 14,827 (0.2) 2,006 (0.1) 12,821 (0.3) Number of previous booster doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent original/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1)	No comorbidities	8.579.525 (61.7)	2,783,512 (42,6)	1.276.771 (49.0)	1.506.741 (38.3)
Number of previous booster doses 20,21 (0.1) 20,22 (0.1) 20,22 (0.1) 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Mosting 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product Pfizer (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) 0 (0.0) Pfizer (bivalent original/BA.1) 11 (0.0) 10 (0.0) 10 (0.0) 10 (0.0) Pfizer (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Original/BA.4/BA.5) 24,963 (0.4)	Missing	25.974 (0.2)	14.827 (0.2)	2.006 (0.1)	12.821 (0.3)
doses 0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (bivalent 0 0 99 (0.0) <td>Number of previous booster</td> <td></td> <td>_ ,, (,,,</td> <td>_//</td> <td>/ (/</td>	Number of previous booster		_ ,, (,,,	_//	/ (/
0 1,598,896 (11.5) 31,608 (0.5) 16,461 (0.6) 15,147 (0.4) 1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (monovalent) 139 (0.0) 79 (0.0) 40 (0.0) Moderna (bivalent 0 0 10 (0.0) 10 (0.0) Pfizer (bivalent original/BA.1) 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (bivalent 0 10 (0.0) 10 (0.0) 10 (0.0) 10 (0.0)	doses				
1 7,711,858 (55.4) 467,250 (7.2) 259,506 (10.0) 207,744 (5.3) 2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (bivalent 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 98 (0.0) 5 (0.0) 93 (0.0) Original/BA.4/BA.5) 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5)	0	1,598,896 (11.5)	31,608 (0.5)	16,461 (0.6)	15,147 (0.4)
2 4,033,888 (29.0) 4,229,639 (64.7) 1,443,946 (55.5) 2,785,693 (70.9) 3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 0 10 (0.0) 10 (0.0) Pfizer (bivalent original/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 0 0 93 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 99,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Original/BA.4/BA.5) 3 (0.0) <td>1</td> <td>7,711,858 (55.4)</td> <td>467,250 (7.2)</td> <td>259,506 (10.0)</td> <td>207,744 (5.3)</td>	1	7,711,858 (55.4)	467,250 (7.2)	259,506 (10.0)	207,744 (5.3)
3 546,308 (3.9) 1,507,255 (23.1) 721,889 (27.7) 785,366 (20.0) 4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (monovalent) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent cipinal/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent cipinal/BA.4/BA.5) 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 10 (0.0)	2	4,033,888 (29.0)	4,229,639 (64.7)	1,443,946 (55.5)	2,785,693 (70.9)
4 16,925 (0.1) 296,458 (4.5) 161,663 (6.2) 134,795 (3.4) 5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent original/BA.1) 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent original/BA.1) 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent original/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent original/BA.4/BA.5) 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0)	3	546.308 (3.9)	1.507.255 (23.1)	721.889 (27.7)	785.366 (20.0)
5 44 (0.0) 1,514 (0.0) 687 (0.0) 827 (0.0) Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 10 (0.0) 10 (0.0) 10 (0.0) Pfizer (bivalent 0 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0) <td>4</td> <td>16.925 (0.1)</td> <td>296.458 (4.5)</td> <td>161.663 (6.2)</td> <td>134.795 (3.4)</td>	4	16.925 (0.1)	296.458 (4.5)	161.663 (6.2)	134.795 (3.4)
Missing 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Vaccine product Pfizer (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 10 (0.0) Missing 15 (0.0) 5 (0.0) <td>5</td> <td>44 (0.0)</td> <td>1.514 (0.0)</td> <td>687 (0.0)</td> <td>827 (0.0)</td>	5	44 (0.0)	1.514 (0.0)	687 (0.0)	827 (0.0)
Vaccine product 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 10 (0.0) 10 (0.0) 10 (0.0) Pfizer (XBB.15) 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Missing	5 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pfizer (monovalent) 75,915 (1.2) 13,953 (0.5) 61,962 (1.6) Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Vaccine product	- ()	- ()		C (0.0)
Moderna (monovalent) 139 (0.0) 79 (0.0) 60 (0.0) Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 0 10 (0.0) 10 (0.0) Moderna (bivalent 0 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Pfizer (monovalent)		75.915 (1.2)	13,953 (0.5)	61,962 (1,6)
Pfizer (bivalent original/BA.1) 4,691 (0.1) 676 (0.0) 4,015 (0.1) Moderna (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 0 11 (0.0) 1 (0.0) 10 (0.0) Moderna (bivalent 0 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 0 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Moderna (monovalent)		139 (0.0)	79 (0 0)	60 (0 0)
Moderna (bivalent (bis) (bis) (bis) (bis) (bis) (bis) Moderna (bivalent 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Pfizer (hivalent original/BA 1)		4 691 (0 1)	676 (0.0)	4 015 (0 1)
original/BA.1) 11 (0.0) 1 (0.0) 10 (0.0) Pfizer (bivalent 11 (0.0) 1 (0.0) 10 (0.0) Original/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Moderna (bivalent		1,001 (0.1)	070 (0.07	1,010 (0.1)
Pfizer (bivalent 11 (0.0) 10 (0.0) Pfizer (bivalent 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	original/BA 1)		11 (0 0)	1 (0 0)	10 (0 0)
original/BA.4/BA.5) 24,963 (0.4) 2,561 (0.1) 22,402 (0.6) Moderna (bivalent 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Pfizer (hivalent		11 (0.0)	1 (0.0)	10 (0.0)
Moderna (bivalent 24,303 (0.4) 2,301 (0.1) 22,402 (0.0) Moderna (bivalent 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	original/BA 1/BA 5)		24 963 (0 4)	2 561 (0 1)	22 402 (0.6)
original/BA.4/BA.5) 98 (0.0) 5 (0.0) 93 (0.0) Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Moderna (hivalent		24,303 (0.4)	2,501 (0.1)	22,402 (0.0)
Pfizer (XBB.1.5) 6,373,342 (97.5) 2,581,821 (98.8) 3,791,521 (96.5) Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	original/BA 4/BA 5)		98 (0 0)	5 (0 0)	93 (0 0)
Moderna (XBB.1.5) 49,597 (0.8) 99 (0.0) 49,498 (1.4) Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Dfizer (YBB 1 5)		6 272 2/2 (0.0)	2 581 821 (08 8)	2 701 521 (0.0)
Novavax 4,950 (0.1) 4,950 (0.3) 0 (0.0) Other (AZ, others) 3 (0.0) 2 (0.0) 1 (0.0) Missing 15 (0.0) 5 (0.0) 10 (0.0)	Modorna (YBB 1 E)		0,373,342 (37.3) 10 E07 (0.8)	2,301,821 (38.8)	3,731,321 (30.3) AQ AQQ (1 A)
Acceleration Context			/ 950 (0.0)	(0.0) مع (0.2) ۸ مدر (0.2)	0 /0 0
Missing 15 (0.0) 5 (0.0) 10 (0.0) * Vaccination status and time since vaccination were assessed at the and of the individual observation period	$Other (\Lambda 7 others)$		2 (0 0) 2 (0 1)	(0.0) 0.00 (0.3)	1 (0.0)
$\frac{10(0.0)}{10(0.0)}$			5 (0.0) 15 (0.0)	2 (0.0) 5 (0.0)	10.0)
	* Vaccination status and time size	covaccipation ware	LJ (U.U)	the individual charter	10 (0.0)

** High risk comorbidities: immunocompromised conditions with COVID-19 vaccine recommendation; Medium/low risk: non-immunocompromised conditions with COVID-19 vaccine recommendation; No comorbidities: persons without any of the risk comorbidities. (Details are presented in Supplementary material, Annex 3, Table S3

398 Table 2. Number of events (COVID-19 hospitalisations or COVID-19 related deaths), person months at risk

399 by vaccine status, and vaccine effectiveness overall and by time since vaccination for individuals aged 65-

- 400 79 and ≥80 years old, within the seven study sites (Belgium, Denmark, Italy, Navarre-Spain, Norway,
- 401 Portugal, and Sweden), during BA.2.86/JN.1 predominance period up to 25 February 2024, VEBIS-EHR
- 402 network

			Heterogeneity	
	Events	Person-month	VE (95%CI)	I ² (min-max study level VE
				estimates)
Age group 65-79				
Hospitalisations				
Not yet vaccinated	1765	17,778,199	ref	ref
Overall vaccinated (≥14 days)	908	9,962,714	50.2% (44.6; 55.2)	0% (45.3%, NV to 60%, BE)
Vaccinated (14-89 days)	813	6,476,931	50.9% (45.1; 56.1)	0% (48%, NO to 62%, BE)
Vaccinated (90-179 days)	91	2,801,147	47.3% (32; 59.1)	0% (-30.1%, NV to 67%, SE)
Deaths				
Not yet vaccinated	256	15,892,126	ref	
Overall vaccinated (≥14 days)	151	7,827,952	57.5% (41.5; 69.1)	23.2% (17%, SE to 68.1%, DK)
Vaccinated (14-89 days)	130	4,557,449	59.2% (41.3; 71.7)	32.9% (25%, SE to 68%, PT)
Vaccinated (90-179 days)	7	778,475	54.0% (-16.8; 81.9)	0% (54%, PT to 54%, PT)
Age group ≥80 years				
Hospitalisations				
Not yet vaccinated	2130	7,011,410	ref	ref
Overall vaccinated (≥14 days)	1306	4,111,559	40.7% (35; 45.8)	0% (29%, BE to 48%, DK)
Vaccinated (14-89 days)	1167	2,664,791	42.0% (36.3; 47.1))	0% (25%, BE to 48.2%, NV)
Vaccinated (90-179 days)	139	1,447,525	35.9% (11.2; 53.7)	38.6% (-1%, IT to 68.5%, DK)
Deaths				
Not yet vaccinated	570	6,576,524	ref	ref
Overall vaccinated (≥14 days)	Overall vaccinated (≥14 389 3,435,771 4 days)	48.4% (38.4; 56.8)	10.1% (36%, NO to 70%, SE)	
Vaccinated (14-89 days)	330	2,407,183	51.2% (41.9; 59)	0% (43%, NO to 71%, SE)
Vaccinated (90-179 days)	55	856,482	9.4% (-85.5; 55.8)	77.2% (-159%, IT to 51%, PT)

VE: vaccine effectiveness, CI: Confidence Interval, BE: Belgium, DK: Denmark, IT: Italy; NO: Norway, NV: Navarre, PT: Portugal, SE: Sweden

VE = one minus the pooled confounder-adjusted hazard ratio at study level using a Cox regression time dependent model (confounder variables used in each study site are available in Annex 3 and 4 of the Supplementary material.